UK Markets closed

Freeline Therapeutics Holdings plc (FRLN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6200+0.0089 (+1.46%)
As of 03:43PM EST. Market open.

Freeline Therapeutics Holdings plc

Stevenage Bioscience Catalyst
Gunnels Wood Road
Stevenage SG1 2FX
United Kingdom
44 14 3890 6870

Full-time employees235

Key executives

NameTitlePayExercisedYear born
Mr. Michael J. Parini J.D.CEO, COO, Pres & Exec. Director1.13MN/A1975
Dr. Amit Chunilal Nathwani M.D., Ph.D.Founder, Independent Clinical & Scientific Advisor and Director513kN/A1960
Dr. Markus Horer Ph.D.Founder, CTO & Managing Director GmbHN/AN/A1967
Mr. James BircherChief Technical Operations OfficerN/AN/A1969
Dr. Pamela Foulds M.D.Chief Medical OfficerN/AN/A1970
Mr. Paul M. SchneiderChief Financial OfficerN/AN/AN/A
Dr. Henning R. Stennicke Ph.D.Chief Scientific OfficerN/AN/A1968
Arne Naeveke Ph.D.VP & Head of Corp. CommunicationsN/AN/AN/A
Ms. Nicole Jones SPHRChief People OfficerN/AN/AN/A
Dr. Alison Long M.D., Ph.D.Interim Chief Medical Officer, Sr. VP & Head of Clinical Devel.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Corporate governance

Freeline Therapeutics Holdings plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.